[Brain metastases in breast cancer. Epidemiology and natural history. The Institut Curie experience]
Related Experiment Video
Updated: Jun 2, 2026

Modeling Brain Metastasis Via Tail-Vein Injection of Inflammatory Breast Cancer Cells
Published on: February 4, 2021
Julie Gachet1, Julie Giroux, Véronique Girre
1Institut Curie, département d'oncologie médicale, 26, rue d'Ulm, 75005 Paris, France.
Abstract:
Breast cancer is the second cause for brain metastases. Their incidence is rising, partly due to the therapeutic improvements which alter the natural history of breast cancer. Predictive factors for brain metastases have been identified: HER2 oncogene overexpression, lack of expression of hormone receptors, young age and triple negative status. Brain metastases prognosis remains poor with a median survival shorter than 1 year, except for solitary lesions treated by surgery or radiosurgery. We have analysed two series of data from Institut Curie (Paris and Saint-Cloud). In women younger than 65 years, with HER2 negative breast carcinoma, median survival was 7.1 months. In women older than 65 years, median survival was 4 months.

